Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Spinal Cord Injury, Muscle Spasticity
Interventions
Fampridine-SR, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 33 more
Completed Phase 3 Interventional Results available

Study of Oral Fampridine-SR in Multiple Sclerosis

NCT00127530
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Conditions
Multiple Sclerosis
Interventions
Dalfampridine-ER 5mg, Dalfampridine-ER 10mg, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
70
States / cities
Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 59 more
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
36
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Berkeley, California + 31 more
Conditions
Gastrointestinal Stromal Tumors
Interventions
Imatinib, Fampridine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
La Jolla, California
Conditions
Nerve Injury, Prostate Cancer
Interventions
4-Aminopyridine, Placebo
Drug · Other
Lead sponsor
John Elfar
Other
Eligibility
45 Years to 75 Years · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Tucson, Arizona • Rochester, New York
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
38
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Berkeley, California + 33 more
Conditions
Multiple Sclerosis
Interventions
fampridine, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 70 Years
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Cullman, Alabama • Phoenix, Arizona • San Diego, California + 12 more
Conditions
Multiple Sclerosis
Interventions
Placebo, 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP), 15 mg fampridine-SR (4-aminopyridine, 4-AP), 20 mg fampridine-SR (4-aminopyridine, 4-AP)
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 19 more
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 24 more
Conditions
Spinal Cord Injury, Muscle Spasticity
Interventions
Fampridine-SR, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Long Beach, California • Sacramento, California + 23 more
Completed Phase 2Phase 3 Interventional Results available

Ampyra for Optic Neuritis in Multiple Sclerosis

NCT01337986
Conditions
Multiple Sclerosis, Optic Neuritis
Interventions
Dalfampridine/Placebo, Placebo/Dalfampridine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR b.i.d. (Twice Daily)
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 17 more
Conditions
Spinal Cord Injury
Interventions
Dalfampridine, Placebo
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
West Orange, New Jersey